Spectral Platforms
Spectral Platforms is pioneering rapid diagnostic solutions in clinical microbiology, focusing on eliminating time-consuming steps in traditional microbiology to enable faster, more accurate detection and characterization of pathogens. Their proprietary technology leverages sensitive detection of bacterial metabolites and redox state changes, providing results in minutes rather than days. The company aims to improve patient outcomes, particularly in sepsis and infectious disease management, by delivering rapid, reliable, and actionable diagnostic information. Spectral Platforms also offers advanced microbiology services and collaborates with leading institutions and regulatory bodies to validate and deploy their innovations.
Spectral Platforms
1851 Huntington Drive, Duarte CA 91010
Patents
Albumin-based non-covalent complexes and methods of use thereof
2025-07-15 • US-12357679-B2
View DetailsSpectroscopic methods to detect and characterize microorganisms
2021-08-31 • US-11105747-B2
View DetailsAlbumin-based non-covalent complexes and methods of use thereof
2019-07-09 • US-10342855-B2
View DetailsAlbumin-based non-covalent complexes and methods of use thereof
2018-09-11 • US-10071141-B2
View DetailsWhat We Do
A rapid diagnostic test that detects the presence of any pathogenic microorganism in blood within 30 minutes of sample availability. Utilizes detection of bacterial metabolites and changes to albumin via Raman spectroscopy. Intended for triage of patients at risk of sepsis and to initiate timely therapeutic measures. Validated in clinical studies and protected by issued patents.
A test that sub-classifies bacteria in clinical samples and characterizes antimicrobial susceptibility (AST) with results equivalent to CLSI standards, including for polymicrobial samples. Provides results in 8 hours for blood and 6 hours for urine samples, enabling prescription of in-vitro active antibiotics from the second dose onward. Uses proprietary algorithms for phenotype characterization and MIC conversion.
A pathogen ID/AST test for urine samples, comprising a software-controlled plate reader and test kit. Delivers results on pathogen presence, subclassification, concentration, and antimicrobial susceptibility within 8 hours. Designed to improve outcomes in urinary tract infections and urosepsis by enabling faster, more accurate therapy decisions. Available as Research Use Only; FDA process started.
A proprietary media-based test for differential detection and diagnosis of Candida auris and related species. Implemented on a 96-well plate, with visual or automated plate reader readout. Designed to address challenges in traditional chromogenic media and improve accuracy in identifying multidrug-resistant fungal infections. Status: Coming soon.
Maintenance of human Airway Epithelial Cells (hAEC) in Air-liquid interface (ALI) format with stringent quality control, aerosol exposure chamber for controlled exposures, and a range of cytotoxic and mutagenic cell damage assays. Includes high throughput cell viability, mutagenic damage (Ames, MTS, micronucleus, Comet Assays), and pathogen decontamination studies (surface and airborne) using UV exposure. Sponsors include the US FDA, Bonutti Technologies (UVCEED), and Wavelengths UV.
Application Area
Show More (2)Biologics
Diagnostics
Digital Health Technologies
Show More (1)Services
Key People
News & Updates
Spectral Platforms was one of 10 Step 1 winners in the AMR (Antimicrobial Resistance) Challenge, recognizing innovation in rapid diagnostics.
Patent issued for albumin-based non-covalent complexes and methods of use, foundational to the company's diagnostic technology.
USPTO issued a notice of allowance for a key patent application, strengthening the company's IP portfolio.
Explores surprising scientific findings from jellyfish and their medical implications.
Discusses approaches and findings related to minimizing side effects of medicines.
Examines why the flu virus does not spread as expected and the implications for public health.